FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237262022> ?p ?o ?g. }

• W4237262022 endingPage "112" @default.
• W4237262022 startingPage "106" @default.
• W4237262022 abstract "Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting the synovium of joints, tendons, and some extra-articular sites. RA prevalence in Latin America ranges from 0.4 to 1.6%. Early treatment of RA translates into a substantial reduction in the cost to society. In light of this, early disease clinics are being established in some countries. Barriers to RA management, such as delay in referral to rheumatologists and limited access to therapy, have been identified. Evidence-based treatment guidelines have been adapted by countries according to their own situations. The need for keeping accurate records of biologics prescribed has been addressed by biologic registries, thereby contributing toward a better understanding of rheumatic diseases and their treatment. Current biologics include the tumor necrosis factor (TNF)-α inhibitors (etanercept, infliximab, and adalimumab), B-cell depletion agent (rituximab), interleukin-6 receptor blocker (tocilizumab), and T-cell co-stimulatory blocker (abatacept). Future therapies include kinase inhibitors (tofacitinib and fostamatinib), alternative TNF-α inhibitors (golimumab and certolizumab), and biosimilars. La artritis reumatoide (AR) es una enfermedad sistémica e inflamatoria que afecta la membrana sinovial de las articulaciones, los tendones y algunos sitios extra-articulares. La prevalencia de la AR en Latinoamérica se encuentra entre 0.4–1.6%. El tratamiento precoz de la enfermedad se traduce en una reducción del costo para la sociedad. En vista de esto, se han establecido clínicas de AR temprana en varios países de la región. Se han identificado barreras para el tratamiento de la AR como lo son el retraso en la referencia al reumatólogo y limitaciones en el acceso al tratamiento. Varios países han desarrollado y adaptado guías para el tratamiento basadas en la evidencia y en sus propias realidades. La necesidad de tener registros detallados de las prescripciones de biológicos ha sido abordada con registros de biológicos lo que llevará a un mejor entendimiento de las enfermedades reumáticas y su tratamiento. Los biológicos disponibles en la actualidad son los inhibidores del factor de necrosis tumoral (TNF)-α (etanercept, infliximab y adalimumab), un agente depletor de células B (rituximab), un bloqueador del receptor de interleucina-6 (tocilizumab) y un bloqueador de la co-estimulación de células T (abatacept). En el futuro se incluirán los inhibidores de cinasas (tofacitinib y fostamatinib) e inhibidores del TNF-α alternativos (golimumab y certolizumab) y biosimilares." @default.
• W4237262022 created "2022-05-12" @default.
• W4237262022 creator A5013851404 @default.
• W4237262022 creator A5022871158 @default.
• W4237262022 creator A5050429859 @default.
• W4237262022 creator A5077020050 @default.
• W4237262022 creator A5078533760 @default.
• W4237262022 date "2013-03-01" @default.
• W4237262022 modified "2023-10-01" @default.
• W4237262022 title "Current therapies in rheumatoid arthritis: A Latin American perspective" @default.
• W4237262022 cites W1424849964 @default.
• W4237262022 cites W1967544396 @default.
• W4237262022 cites W1980563301 @default.
• W4237262022 cites W1984009427 @default.
• W4237262022 cites W1996389186 @default.
• W4237262022 cites W1997154374 @default.
• W4237262022 cites W2009379422 @default.
• W4237262022 cites W2017842174 @default.
• W4237262022 cites W2028200430 @default.
• W4237262022 cites W2040185943 @default.
• W4237262022 cites W2048618042 @default.
• W4237262022 cites W2060744899 @default.
• W4237262022 cites W2107834854 @default.
• W4237262022 cites W2111153776 @default.
• W4237262022 cites W2114308202 @default.
• W4237262022 cites W2118084423 @default.
• W4237262022 cites W2120426416 @default.
• W4237262022 cites W2124670599 @default.
• W4237262022 cites W2128952811 @default.
• W4237262022 cites W2131754054 @default.
• W4237262022 cites W2131781864 @default.
• W4237262022 cites W2134171514 @default.
• W4237262022 cites W2136473687 @default.
• W4237262022 cites W2140965629 @default.
• W4237262022 cites W2150301963 @default.
• W4237262022 cites W2153919578 @default.
• W4237262022 cites W2163817180 @default.
• W4237262022 cites W2166287921 @default.
• W4237262022 cites W2168792642 @default.
• W4237262022 cites W2501753017 @default.
• W4237262022 cites W4233021914 @default.
• W4237262022 cites W4363603928 @default.
• W4237262022 cites W58316457 @default.
• W4237262022 cites W81489155 @default.
• W4237262022 doi "https://doi.org/10.1016/j.reumae.2013.01.007" @default.
• W4237262022 hasPublicationYear "2013" @default.
• W4237262022 type Work @default.
• W4237262022 citedByCount "2" @default.
• W4237262022 countsByYear W42372620222018 @default.
• W4237262022 countsByYear W42372620222021 @default.
• W4237262022 crossrefType "journal-article" @default.
• W4237262022 hasAuthorship W4237262022A5013851404 @default.
• W4237262022 hasAuthorship W4237262022A5022871158 @default.
• W4237262022 hasAuthorship W4237262022A5050429859 @default.
• W4237262022 hasAuthorship W4237262022A5077020050 @default.
• W4237262022 hasAuthorship W4237262022A5078533760 @default.
• W4237262022 hasConcept C126322002 @default.
• W4237262022 hasConcept C17991360 @default.
• W4237262022 hasConcept C2776215756 @default.
• W4237262022 hasConcept C2776260265 @default.
• W4237262022 hasConcept C2777138892 @default.
• W4237262022 hasConcept C2777178219 @default.
• W4237262022 hasConcept C2777226972 @default.
• W4237262022 hasConcept C2777575956 @default.
• W4237262022 hasConcept C2778886723 @default.
• W4237262022 hasConcept C2779338263 @default.
• W4237262022 hasConcept C2779605438 @default.
• W4237262022 hasConcept C2780132546 @default.
• W4237262022 hasConcept C2780653079 @default.
• W4237262022 hasConcept C2781290027 @default.
• W4237262022 hasConcept C71924100 @default.
• W4237262022 hasConceptScore W4237262022C126322002 @default.
• W4237262022 hasConceptScore W4237262022C17991360 @default.
• W4237262022 hasConceptScore W4237262022C2776215756 @default.
• W4237262022 hasConceptScore W4237262022C2776260265 @default.
• W4237262022 hasConceptScore W4237262022C2777138892 @default.
• W4237262022 hasConceptScore W4237262022C2777178219 @default.
• W4237262022 hasConceptScore W4237262022C2777226972 @default.
• W4237262022 hasConceptScore W4237262022C2777575956 @default.
• W4237262022 hasConceptScore W4237262022C2778886723 @default.
• W4237262022 hasConceptScore W4237262022C2779338263 @default.
• W4237262022 hasConceptScore W4237262022C2779605438 @default.
• W4237262022 hasConceptScore W4237262022C2780132546 @default.
• W4237262022 hasConceptScore W4237262022C2780653079 @default.
• W4237262022 hasConceptScore W4237262022C2781290027 @default.
• W4237262022 hasConceptScore W4237262022C71924100 @default.
• W4237262022 hasIssue "2" @default.
• W4237262022 hasLocation W42372620221 @default.
• W4237262022 hasOpenAccess W4237262022 @default.
• W4237262022 hasPrimaryLocation W42372620221 @default.
• W4237262022 hasRelatedWork W2118434900 @default.
• W4237262022 hasRelatedWork W2120393706 @default.
• W4237262022 hasRelatedWork W2125430230 @default.
• W4237262022 hasRelatedWork W2293692550 @default.
• W4237262022 hasRelatedWork W2416112349 @default.
• W4237262022 hasRelatedWork W2551193787 @default.
• W4237262022 hasRelatedWork W2935343188 @default.
• W4237262022 hasRelatedWork W3193913808 @default.

• next